Homemultiple sclerosis

  • Celgene to re-file Ozanimod in 1st quarter of 2019

    • May 9, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Mavenclad has even greater treatment effect in Patients with Highly Active Multiple Sclerosis, shows latest data

    • May 3, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Ocrevus reduces response of MS patients to Vaccines, claims latest study

    • May 3, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • EMD Serono using technology to bring MS experience to life

    • May 1, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • New long term data for Copaxone presented by Teva at AAN

    • April 30, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Ph 2 results of Ublituximab (TG-1101) in MS patients announced by TG Therapeutics at AAN 2018

    • April 26, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Ph 2b trial results of MN-166 (ibudilast) in Progressive MS presented at AAN 2018

    • April 26, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • New guidelines for starting MS treatment early and switching issued at AAN 2018

    • April 25, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Switches from Injectables to Fingolimod associated with lower relapse risks, underlines new study

    • April 24, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Results for Ibudilast Phase II trial in progressive MS to be presented at AAN

    • April 20, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more